Zollinger‑Ellison Tumor (Gastrinoma) Signs
What is Zollinger‑Ellison tumor (gastrinoma) signs?
A Zollinger‑Ellison tumor (ZET), also called a gastrinoma, is a rare neuroendocrine tumor that arises from the G‑cells of the pancreas or duodenum. These cells normally produce the hormone gastrin, which stimulates the stomach to release acid. When a gastrinoma forms, it secretes excessive gastrin, leading to very high levels of gastric acid. The resulting acid overload damages the lining of the upper gastrointestinal (GI) tract and causes a distinctive pattern of symptoms often referred to as “Zollinger‑Ellison syndrome.”
Because the tumor’s primary problem is hormone over‑production rather than mass effect, the signs (observable clinical findings) may include ulceration, ulcer‑related complications, and biochemical evidence of hypergastrinemia. Understanding these signs helps clinicians differentiate ZET from more common peptic ulcer disease.
Common Causes
While a gastrinoma itself is the direct cause of the syndrome, several underlying conditions can predispose to its development or mimic its presentation. The most frequent associations are:
- Multiple Endocrine Neoplasia type 1 (MEN‑1): A hereditary syndrome that includes tumors of the parathyroid, pituitary, and pancreatic endocrine glands.
- Familial isolated gastrinoma: Rare inherited form without other MEN‑1 features.
- Pancreatic neuroendocrine tumors (PNETs): Other hormonally active tumors that may coexist.
- Chronic atrophic gastritis: Can increase gastrin levels, though usually not to the degree seen in ZET.
- Helicobacter pylori infection: Causes ulcer disease that may be confused with gastrinoma‑related ulcers.
- Proton‑pump inhibitor (PPI) overuse: Long‑term suppression of acid can cause a feedback rise in gastrin, complicating lab interpretation.
- Renal failure: Impaired clearance of gastrin can lead to modest elevations.
- Idiopathic hypergastrinemia: Rare, unexplained high gastrin levels without tumor.
- Other neuroendocrine tumors (e.g., carcinoid): May secrete hormones that affect gastrin regulation.
- Autoimmune gastritis: Destruction of acid‑producing cells leads to compensatory gastrin rise.
Associated Symptoms
Symptoms arise from the combination of excess acid and local tumor effects. The classic “triad” of Zollinger‑Ellison syndrome includes:
- Severe peptic ulcer disease: Ulcers may be multiple, refractory to treatment, and occur in unusual locations such as the jejunum.
- Abdominal pain: Often epigastric, worsening after meals due to increased acid secretion.
- Diarrhea or steatorrhea: Acid inactivates pancreatic enzymes and damages the mucosa, leading to malabsorption.
Additional symptoms that frequently accompany the triad include:
- Nausea and vomiting, sometimes with bile.
- Weight loss or failure to thrive (especially in children).
- Gastro‑esophageal reflux disease (GERD) that is resistant to standard therapy.
- Bleeding from ulcers (hematemesis or melena).
- Fatigue and iron‑deficiency anemia due to chronic blood loss.
- Syncope or dizziness from severe volume depletion secondary to diarrhea.
- Signs of metastatic disease (e.g., liver lesions, bone pain) in advanced cases.
When to See a Doctor
Because ulcer disease is common, it can be easy to dismiss early signs. Seek medical attention promptly if you experience any of the following:
- Recurrent or persistent abdominal pain that does not improve with over‑the‑counter antacids or PPIs.
- Four or more episodes of ulcer‑related pain within a 12‑month period.
- Vomiting of blood or coffee‑ground material, or black, tarry stools.
- Unexplained weight loss of more than 5 % of body weight in a month.
- Chronic watery diarrhea (≥3 stools per day) that interferes with daily activities.
- History of MEN‑1 or a close family member with a gastrinoma.
- Failure of ulcers to heal after 8–12 weeks of high‑dose PPI therapy.
Diagnosis
Diagnosing Zollinger‑Ellison syndrome involves a stepwise approach that combines clinical suspicion, laboratory testing, imaging, and sometimes endoscopic evaluation.
1. Laboratory evaluation
- Fasting serum gastrin level: A value > 1,000 pg/mL is highly suggestive, especially if the gastric pH is low (< 2). Levels between 150–1,000 pg/mL require further confirmation.
- Secretin stimulation test: Intravenous secretin normally suppresses gastrin; in gastrinoma, gastrin paradoxically rises ≥ 120 pg/mL.
- Stool alkaline phosphatase or fecal fat: To assess malabsorption when diarrhea is prominent.
2. Imaging studies
- Endoscopic ultrasound (EUS): High‑resolution view of pancreas and duodenum; can detect tumors as small as 2–3 mm.
- Multiphasic contrast‑enhanced CT or MRI: Provides anatomic detail of primary lesions and metastatic spread (especially to liver and lymph nodes).
- Somatostatin receptor scintigraphy (Octreoscan) or Ga‑68 DOTATATE PET/CT: Detects neuroendocrine tumor tissue that expresses somatostatin receptors.
3. Endoscopic evaluation
- Upper endoscopy (EGD): Identifies ulcer locations, assesses for bleeding, and allows biopsy of suspicious lesions.
- Duodenal brushings or biopsies: May obtain tumor cells when the lesion is not clearly visualized.
4. Histopathology
If tissue is available, pathology confirms a well‑differentiated neuroendocrine tumor (WHO grade 1–2) that stains positive for gastrin, chromogranin A, and synaptophysin.
Treatment Options
The therapeutic strategy combines control of acid hypersecretion, removal or reduction of tumor burden, and management of metastatic disease.
Medical Management – Controlling Acid
- High‑dose proton pump inhibitors (PPIs): Omeprazole 40–80 mg daily, esomeprazole 40–80 mg, or equivalent. PPIs are the cornerstone because they reduce acid output regardless of gastrin levels.
- H2‑receptor antagonists: May be added for breakthrough symptoms (e.g., famotidine 40 mg twice daily).
- Antacids: Useful for immediate relief of severe heartburn.
- Somatostatin analogues (e.g., octreotide, lanreotide): Suppress gastrin release and can shrink tumor size, especially in metastatic disease.
Surgical Treatment
- Curative resection: For localized gastrinomas (< 2 cm) without metastasis, en‑bloc removal of the primary tumor (pancreaticoduodenectomy, distal pancreatectomy, or duodenal excision) offers the best long‑term outcome.
- Debulking surgery: In patients with liver metastases, removing > 90 % of tumor burden can improve symptom control and survival.
- Liver‑directed therapies: Radiofrequency ablation, hepatic artery embolization, or peptide‑receptor radionuclide therapy (PRRT) for unresectable liver disease.
Systemic Therapies
- Targeted agents: Everolimus (mTOR inhibitor) and sunitinib (tyrosine‑kinase inhibitor) have FDA approval for advanced pancreatic neuroendocrine tumors.
- Chemotherapy: Reserved for high‑grade (poorly differentiated) tumors; regimens may include streptozocin‑based combinations.
- PRRT (Lutathera – 177Lu‑DOTATATE): Delivers radiation directly to somatostatin‑receptor‑positive cells, showing durable disease control in many studies.
Home & Lifestyle Measures
- Take PPIs exactly as prescribed – usually 30 minutes before a meal.
- Avoid trigger foods that increase acid (spicy, fatty, caffeine‑rich, acidic beverages).
- Stay hydrated; replace electrolytes if diarrhea is severe.
- Small, frequent meals reduce gastric stimulation.
- Stop smoking and limit alcohol, both of which worsen ulcer disease.
Prevention Tips
Because most gastrinomas are sporadic, primary prevention is limited. However, risk reduction and early detection are possible for certain groups:
- Genetic counseling: Individuals with a family history of MEN‑1 should undergo genetic testing and regular surveillance (annual fasting gastrin, imaging).
- Eradicate H. pylori infection: Though it does not cause gastrinoma, treating the infection lowers ulcer‑related complications that could mask ZET.
- Monitor long‑term PPI users: Periodic measurement of fasting gastrin after 1–2 years of high‑dose therapy can identify hypergastrinemia early.
- Healthy lifestyle: A balanced diet, regular exercise, and avoidance of tobacco reduce overall GI inflammation.
- Prompt evaluation of refractory ulcers: If an ulcer fails to heal within 8 weeks, a work‑up for gastrinoma should be initiated.
Emergency Warning Signs
If any of the following occur, seek immediate emergency care (call 911 or go to the nearest emergency department):
- Vomiting of bright red blood or material that looks like coffee grounds.
- Black, tarry stools indicating significant GI bleeding.
- Sudden, severe abdominal pain that does not improve with rest or medication.
- Signs of shock: rapid heartbeat, low blood pressure, pale/clammy skin, dizziness or fainting.
- Persistent vomiting that leads to dehydration (dry mouth, decreased urine output, dizziness).
- Neurological changes such as confusion or seizures (rare, but may signal severe electrolyte imbalance from diarrhea).
Early recognition of Zollinger‑Ellison tumor signs and prompt evaluation can dramatically improve quality of life and, in many cases, cure the disease.
References:
- Mayo Clinic. “Zollinger‑Ellison syndrome.” mayoclinic.org. Accessed June 2024.
- National Cancer Institute. “Pancreatic Neuroendocrine Tumors Treatment (PDQ®)–Health Professional Version.” cancer.gov. 2023.
- American College of Gastroenterology. “Guidelines for Diagnosis and Management of Peptic Ulcer Disease.” gi.org. 2022.
- World Health Organization. “Classification of Tumors of the Digestive System, 5th Edition.” 2022.
- Cleveland Clinic. “Zollinger‑Ellison Syndrome – Symptoms, Diagnosis, Treatment.” clevelandclinic.org. 2023.
- European Neuroendocrine Tumor Society (ENETS) Consensus Guidelines for Gastric Neuroendocrine Tumors, 2021.